Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 548272, 3 pages
http://dx.doi.org/10.1155/2014/548272
Case Report

Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report

1Department of Internal Medicine, Detroit Receiving Hospital/University Health Center, Suite 2E, 4201 St. Antoine Street, Detroit, MI 48201, USA
2Pharmacy Department, Detroit Medical Center, Detroit, MI, USA
3Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

Received 23 July 2014; Accepted 28 October 2014; Published 13 November 2014

Academic Editor: Kiyotaka Kawauchi

Copyright © 2014 Naveen Nannapaneni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. F. Peacock, M. M. Gearhart, and R. M. Mills, “Emergency management of bleeding associated with old and new oral anticoagulants,” Clinical Cardiology, vol. 35, no. 12, pp. 730–737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Fawole, H. A. Daw, and M. A. Crowther, “Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban,” Cleveland Clinic Journal of Medicine, vol. 80, no. 7, pp. 443–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Gordon, T. C. Fabian, M. D. Lee, and M. Dugdale, “Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies,” The Journal of Trauma and Acute Care Surgery, vol. 75, no. 3, pp. 475–486, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. N. I. Awad and C. Cocchio, “Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy,” P and T, vol. 38, no. 11, pp. 696–701, 2013. View at Google Scholar · View at Scopus
  7. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Thigpen and N. A. Limdi, “Reversal of oral anticoagulation,” Pharmacotherapy, vol. 33, no. 11, pp. 1199–1213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Godier, A. Miclot, B. Le Bonniec et al., “Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model,” Anesthesiology, vol. 116, no. 1, pp. 94–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Franchini and G. Lippi, “Prothrombin complex concentrates: an update,” Blood Transfusion, vol. 8, no. 3, pp. 149–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Perzborn, A. Gruber, H. Tinel et al., “Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates,” Thrombosis and Haemostasis, vol. 110, no. 1, pp. 162–172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Perzborn, S. Heitmeier, L. Volker, and A. Buchmuller, “Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro,” Thrombosis Research, vol. 133, no. 4, pp. 671–681, 2014. View at Publisher · View at Google Scholar
  13. B. Sørensen, D. R. Spahn, P. Innerhofer, M. Spannagl, and R. Rossaint, “Clinical review: Prothrombin complex concentrates—evaluation of safety and thrombogenicity,” Critical Care, vol. 15, no. 1, pp. 201–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Nitzki-George, I. Wozniak, and J. A. Caprini, “Current state of knowledge on oral anticoagulant reversal using procoagulant factors,” Annals of Pharmacotherapy, vol. 47, no. 6, pp. 841–855, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti, “Pharmacology and management of the vitamin k antagonists: american college of chest physicians evidence-based clinical practice guidelines,” Chest, vol. 133, no. 6, pp. 160–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Babilonia and T. Trujillo, “The role of prothrombin complex concentrates in reversal of target specific anticoagulants,” Thrombosis Journal, vol. 12, no. 1, article 8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Lu, F. R. Deguzman, S. J. Hollenbach et al., “A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,” Nature Medicine, vol. 19, no. 4, pp. 446–451, 2013. View at Publisher · View at Google Scholar · View at Scopus